Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New 2-substituted indoloquinone mitomycin analogues.

B S Iyengar1, W A Remers, J J Catino

  • 1Department of Pharmaceutical Sciences, College of Pharmacy, University of Arizona, Tucson 85721.

Journal of Medicinal Chemistry
|August 1, 1989
PubMed
Summary

New indoloquinone analogues were synthesized to improve DNA alkylation selectivity. Some 5-methoxy and 5-aziridinyl derivatives showed enhanced cytotoxic activity against human tumor cell lines compared to mitomycin C.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chemistry and pharmacology of imexon and related cyanoaziridines.

Current medicinal chemistry·2012
Same author

Analogues of amonafide and azonafide with novel ring systems.

Journal of medicinal chemistry·2000
Same author

Intracellular localization of 6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h]isoquino line-1,3-diones (azonafides) is not the limiting factor for their cytotoxicity: an in vitro confocal microscopy study.

Anti-cancer drugs·1999
Same author

Novel antitumor 2-cyanoaziridine-1-carboxamides.

Journal of medicinal chemistry·1999
Same author

Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.

Cancer chemotherapy and pharmacology·1999
Same author

Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.

Cancer research·1998

Area of Science:

  • Medicinal Chemistry
  • Organic Synthesis
  • Cancer Biology

Background:

  • Previous indoloquinone analogues (acetates, carbamates) showed limited activity due to potential over-reactivity.
  • A hypothesis suggested that controlled bioactivation via reduction potential modulation could enhance efficacy.

Purpose of the Study:

  • To synthesize novel indoloquinone analogues with modified substituents.
  • To investigate the impact of these modifications on reduction potential and bioactivation rates.
  • To evaluate the cytotoxic and in vivo activity of new analogues against cancer models.

Main Methods:

  • Synthesis of 5-methoxyindoloquinones, 5-aziridinylindoloquinones, and 5-aminoindoloquinones.
  • Cytotoxicity assays against human tumor cell lines.

Related Experiment Videos

  • In vivo assays using the P388 leukemia mouse model.
  • Preparation of a complex 2-(1-hydroxyethyl)carbamate analogue.

    • Main Results:

    • 5-methoxyindoloquinones were potent cytotoxics against cell lines but inactive in vivo.
    • Two 5-aziridinylindoloquinones exceeded mitomycin C potency against cell lines; one showed in vivo activity.
    • 5-amino analogues were less potent than mitomycin C.
    • A complex carbamate analogue exhibited reduced potency.

    Conclusions:

    • Modulating substituents on the indoloquinone core can influence cytotoxic and in vivo activity.
    • 5-aziridinylindoloquinones represent promising leads for further anticancer drug development.
    • Optimizing bioactivation pathways remains crucial for effective DNA-crosslinking agents.